EGFR and lung carcinoma: As T790M-EGFR may play a role in both intrinsic and acquired EGFR-TKI resistance in lung cancer, it would be useful to test concurrent combinatorial MET–EGFR inhibitors in clinical trials on lung cancer patients refractory to erlotinib/gefitinib.